share_log

GlaxoSmithKline | 6-K: Viiv Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-Acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses

GlaxoSmithKline | 6-K: Viiv Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-Acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses

葛兰素史克 | 6-K:Viiv Healthcare公布卡Cabotegravir长效注射剂研究配方的I期临床试验结果,两次给药间隔至少四个月
SEC announcement ·  03/05 06:13
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息